Inas Ahmed Saeed

Abstract :

Shigellosis is a highly contagious diarrheal illness caused by Shigella bacteria, posing a major global health challenge, particularly in regions with inadequate sanitation. The disease spreads primarily through the fecal-oral route, disproportionately affecting children under five and individuals with weakened immune systems. The pathogenesis of shigellosis involves the invasion and replication of Shigella within the colonic epithelium, resulting in intense inflammation and damage to the mucosal lining. Typical symptoms include diarrhea, fever, abdominal cramps, and dysentery. If left untreated, complications such as severe dehydration and hemolytic uremic syndrome can arise. A growing concern in the epidemiology of shigellosis is the rise of antimicrobial resistance, which complicates treatment options. Standard treatments involve rehydration and antibiotics like azithromycin and ciprofloxacin. However, the emergence of multidrug-resistant Shigella strains has underscored the urgent need for new antimicrobial therapies and effective vaccines. Current research is actively exploring alternative treatments to address resistant strains. Prevention and control strategies focus on improving sanitation, promoting hygiene practices such as handwashing, and advancing vaccination efforts. Public health initiatives are critical in reducing transmission by ensuring access to clean water, proper sanitation facilities, and health education. Given the escalating threat of drug resistance and the global impact of shigellosis, there is an urgent need for enhanced surveillance, innovative therapeutic approaches, and stronger prevention measures. Strengthening global health systems and intensifying research efforts are essential to reducing the prevalence of shigellosis, especially in endemic areas.